全文获取类型
收费全文 | 20376篇 |
免费 | 1851篇 |
国内免费 | 267篇 |
专业分类
耳鼻咽喉 | 540篇 |
儿科学 | 1946篇 |
妇产科学 | 179篇 |
基础医学 | 1010篇 |
口腔科学 | 233篇 |
临床医学 | 1896篇 |
内科学 | 1926篇 |
皮肤病学 | 270篇 |
神经病学 | 958篇 |
特种医学 | 2111篇 |
外国民族医学 | 9篇 |
外科学 | 2761篇 |
综合类 | 1742篇 |
现状与发展 | 2篇 |
预防医学 | 1691篇 |
眼科学 | 145篇 |
药学 | 2758篇 |
22篇 | |
中国医学 | 401篇 |
肿瘤学 | 1894篇 |
出版年
2023年 | 500篇 |
2022年 | 788篇 |
2021年 | 1089篇 |
2020年 | 943篇 |
2019年 | 1134篇 |
2018年 | 1191篇 |
2017年 | 855篇 |
2016年 | 806篇 |
2015年 | 736篇 |
2014年 | 1676篇 |
2013年 | 1588篇 |
2012年 | 1166篇 |
2011年 | 1263篇 |
2010年 | 939篇 |
2009年 | 923篇 |
2008年 | 916篇 |
2007年 | 751篇 |
2006年 | 636篇 |
2005年 | 517篇 |
2004年 | 388篇 |
2003年 | 298篇 |
2002年 | 268篇 |
2001年 | 267篇 |
2000年 | 236篇 |
1999年 | 199篇 |
1998年 | 162篇 |
1997年 | 165篇 |
1996年 | 130篇 |
1995年 | 129篇 |
1994年 | 115篇 |
1993年 | 102篇 |
1992年 | 76篇 |
1991年 | 85篇 |
1990年 | 83篇 |
1989年 | 96篇 |
1988年 | 67篇 |
1987年 | 59篇 |
1986年 | 58篇 |
1985年 | 142篇 |
1984年 | 135篇 |
1983年 | 84篇 |
1982年 | 113篇 |
1981年 | 99篇 |
1980年 | 89篇 |
1979年 | 90篇 |
1978年 | 51篇 |
1977年 | 51篇 |
1976年 | 73篇 |
1974年 | 48篇 |
1973年 | 45篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
《Cancer radiothérapie》2022,26(4):611-615
In order to provide more convenient irradiation regimens for patient comfort, radiation facility organization and health expenses, new hypofractionated protocols have been evaluated. Moderately (dose/fraction: 2.3 to 3 Gy), then ultra (dose/fraction: 5.2 to 6.1 Gy) hypofractionated irradiations were first validated. The current question is: is it possible to go forward using extreme hypofractionated regimens (EHR) based on 1 to 3 fractions. Different irradiation techniques are under investigation. However, brachytherapy remains the smartest way to deliver a high dose in a small volume. We report prospective and retrospective study results which evaluated EHR for breast and prostate brachytherapy. While oncological outcome and toxicity profile appear extremely encouraging for low-risk breast cancer after a 1 to 4 fractions (6.25 to 20 Gy/fraction), the use of a single fraction of 19 to 23 Gy appears debatable for prostate cancer. Brachytherapy represents an emblematic example of EHR but longer follow-up and more mature results are awaited in order to specify the right indications and refine the EQD2 calculation method including new biological and technical factors. 相似文献
2.
《Molecular therapy》2022,30(5):1885-1896
- Download : Download high-res image (90KB)
- Download : Download full-size image
3.
4.
《Journal of pediatric surgery》2023,58(5):856-861
Background/PurposeA small number of Hirschsprung disease (HD) patients develop inflammatory bowel disease (IBD)-like symptoms after pullthrough surgery. The etiology and pathophysiology of Hirschsprung-associated IBD (HD-IBD) remains unknown. This study aims to further characterize HD-IBD, to identify potential risk factors and to evaluate response to treatment in a large group of patients.MethodsRetrospective study of patients diagnosed with IBD after pullthrough surgery between 2000 and 2021 at 17 institutions. Data regarding clinical presentation and course of HD and IBD were reviewed. Effectiveness of medical therapy for IBD was recorded using a Likert scale.ResultsThere were 55 patients (78% male). 50% (n = 28) had long segment disease. Hirschsprung-associated enterocolitis (HAEC) was reported in 68% (n = 36). Ten patients (18%) had Trisomy 21. IBD was diagnosed after age 5 in 63% (n = 34). IBD presentation consisted of colonic or small bowel inflammation resembling IBD in 69% (n = 38), unexplained or persistent fistula in 18% (n = 10) and unexplained HAEC >5 years old or unresponsive to standard treatment in 13% (n = 7). Biological agents were the most effective (80%) medications. A third of patients required a surgical procedure for IBD.ConclusionMore than half of the patients were diagnosed with HD-IBD after 5 years old. Long segment disease, HAEC after pull through operation and trisomy 21 may represent risk factors for this condition. Investigation for possible IBD should be considered in children with unexplained fistulae, HAEC beyond the age of 5 or unresponsive to standard therapy, and symptoms suggestive of IBD. Biological agents were the most effective medical treatment.Level of EvidenceLevel 4 相似文献
5.
《Vaccine》2022,40(30):4038-4045
PurposeAs protection from COVID-19 following two doses of the BNT162b2 vaccine showed a time dependent waning, a third (booster) dose was administrated. This study aims to compare the antibody response following the third dose versus the second and to evaluate post-booster seroconversion.MethodsA prospective observational study conducted in Maccabi Healthcare Services. Serial SARS-CoV-2 Spike IgG tests, 1,2,3 and 6 months following the second vaccine dose and one month following the third were obtained. Neutralizing antibody levels were measured in a subset of participants. Per individual SARS-CoV-2 Spike IgG titer ratios were calculated one month after the booster administration compared to titers one month following the second dose and prior to booster.ResultsAmong 110 participants, 56 (51%) were women. Mean age was 61.7 ± 1.9 years and 66 (60%) were immunocompromised. One month after third dose, IgG titers were induced 7.83 (95 %CI 5.25–11.67) folds and 2.40 (95 %CI 1.90–3.03) folds compared to one month after the second, in the immunocompromised and immunocompetent groups, respectively. Of the 17 immunocompromised participants who were seronegative after the second dose, 4 (24%) became seropositive following the third. Comparing the titers prior to the third dose, an increase of 50.7 (95 %CI 32.5–79.1) fold in the immunocompromised group and 25.7 (95 %CI 19.1–34.7) fold in and immunocompetent group, was observed.ConclusionA third BNT162b2 vaccine elicited robust humoral response, superior to the response observed following the second, among immunocompetent and immunocompromised individuals. 相似文献
6.
7.
8.
9.
10.
目的:探讨3D-CRT 低剂量区 V5体积的大小对非小细胞肺癌患者肺功能的影响。方法:收集我院肿瘤科2014年4月~2015年10月收治的46例首次行三维适形放射治疗且顺利完成治疗的非小细胞肺癌患者,对每例患者分别在治疗前以及治疗后的1、3个月进行肺功能检测,分析3D-CRT 低剂量区 V5体积的大小与肺功能变化之间的关系。结果:放疗后1个月的 FEV1%、FVC%值明显高于放疗前且差异均具有显著性。放疗后1个月、3个月的 DLCO%值明显低于放疗前,且放疗前的与放疗后3个月的差异具有显著性;V5≦45%、45%55%三组放疗前后的 FEV1%值和 FVC%值比较差异均不具有显著性。V5≦45%、45%55%三组放疗前后的 DLCO%值均呈逐渐下降趋势,且 V5>55%组的放疗前后 DLCO%值比较差异具有显著性。而 V5≦45%组和45%55%时,DLCO%值降低的趋势更加显著。 相似文献